Knight Cancer signal achievements of 2022
People at the Knight Cancer Institute accomplished a lot in 2022. Through innovative, collaborative research and education, the institute delivers cancer prevention, detection, and care — one...
Category: translational research
A better roadmap for beating a deadly leukemia
Acute myeloid leukemia, or AML, is the most common acute blood cancer in adults — and one of the most difficult to treat. Scientists at Oregon Health & Science University have discovered a...
New approach finds drug combinations to stop cancer
In the future, the most effective cancer drug therapies will likely be combinations that not only target cancer cells but also drive cancer-suppressing responses in non-cancer cells in and around...
Treatment advance for an incurable blood cancer
Researchers are reporting an impressive advance in the treatment of mantle cell lymphoma, a type of blood cancer that is considered incurable. Patients who took the drug ibrutinib in addition to a...
Progress in preventing kidney cancer recurrence
Cancer “adjuvant” therapies are treatments designed to reduce the chances of tumors coming back after surgery. But for decades, attempts to find adjuvant treatments for kidney cancer failed to...
Clinical trial elevates new target for fighting cancers
Researchers have verified a much-needed new target for treating cancers that often become resistant to existing therapies and become deadly. In an early-phase clinical trial, the researchers tested...
How to make more cancers vulnerable to immunotherapies
Cancer immunotherapies called checkpoint inhibitors can bring dramatic, life-saving results – but only for a limited fraction of patients. Aiming to help more patients benefit, researchers in...
Targeted ‘radioligand’ improves survival in advanced prostate cancer
Cancer researchers say they have established a new, life-extending treatment option for men with prostate cancer that has spread and become resistant to hormone therapy. The injected treatment...
Unlocking the combination to target evasive kidney cancers
Roughly one in four people with kidney cancer have a type that does not respond to targeted therapy drugs, leaving no proven treatment options for those whose tumors have started to...
First-in-class drug targets resistant ovarian cancer
Cancer researchers have discovered a way to target a pivotal driver of drug resistance in ovarian cancer, one of the top causes of cancer death in women. The experimental compound, called SU056,...
Experimental drug aims to prevent blood clots without boosting risk of bleeding
Conventional anti-clotting drugs have a big downside: increased risk of internal bleeding. An entirely new class of antithrombotic developed at OHSU and its spin-off biopharmaceutical company,...